Table 1 –
Ongoing clinical trials in prostate cancer with drugs targeting epigenetic factors
| S. no. | Drug | Target | Combination | Phase | Indication | Trial Identifier | Status |
|---|---|---|---|---|---|---|---|
| 1 | Decitabine | DNMT | Enzalutamide | 1, 2 | Metastatic castration-resistant prostate cancer | NCT03709550 | Not yet recruiting |
| 2 | ZEN003694 | BET | Enzalutamide and pembrolizumab | 2 | Metastatic castration-resistant prostate cancer | NCT04471974 | Not yet recruiting |
| 3 | GSK525762 | BET | Abiraterone/prednisone or enzalutamide | 1 | Metastatic castration-resistant prostate cancer | NCT03150056 | Active, not recawing |
| 4 | PLX2853 | BET | Abiraterone/prednisone or olaparib | 1, 2 | Metastatic castration-resistant prostate cancer | NCT04556617 | Recruiting |
| 5 | CCS1477 | p300/CBP | Abiraterone/prednisone or enzalutamide | 1, 2 | Metastatic castration-resistant prostate cancer | NCT03568656 | Recruiting |
| 6 | FT-7051 | p300/CBP | 1 | Metastatic castration-resistant prostate cancer | NCT04575766 | Recruiting | |
| 7 | MS-275 | HDAC | Enzalutamide | 1 | Castration-resistant prostate cancer | NCT03829930 | Recruiting |
| 8 | CPI-1205 | EZH2 | Abiraterone/prednisone or enzalutamide | 1, 2 | Metastatic castration-resistant prostate cancer | NCT03480646 | Active, not recruiting |
| 9 | PF-06821497 | EZH2 | 1 | Metastatic castration-resistant prostate cancer | NCT03460977 | Recruiting | |
| 10 | EPZ-6438 | EZH2 | Abiraterone/prednisone or enzalutamide | 1 | Metastatic castration-resistant prostate cancer | NCT04179864 | Recruiting |
| 11 | SHR2554 | EZH2 | SHR3680 (Novel Anti-Androgen) | 1, 2 | Metastatic castration-resistant prostate cancer | NCT03741712 | Recruiting |
| 12 | DS3201 | EZH1/2 | Ipilimumab | 1 | Metastatic castration-resistant prostate cancer | NCT04388852 | Recruiting |
BET = bromodomain and extraterminal; DNMT = DNA methyltransferase; EZH = Enhancer of Zeste; HDAC = histone deacetylase.